OrbiMed’s Keros Therapeutics KROS Stock Holding History

OrbiMed’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.12M	Hold	759,155	–	–	0.15%	88
2026 Q1	$8.38M	Sell	759,155 -45,057	-6%	-$696K	0.17%	82
2025 Q4	$16.4M	Sell	804,212 -214,522	-21%	-$3.76M	0.33%	67
2025 Q3	$16.1M	Hold	1,018,734	–	–	0.38%	60
2025 Q2	$13.6M	Hold	1,018,734	–	–	0.34%	51
2025 Q1	$10.4M	Hold	1,018,734	–	–	0.25%	61
2024 Q4	$16.1M	Hold	1,018,734	–	–	0.33%	59
2024 Q3	$59.2M	Sell	1,018,734 -250,000	-20%	-$12.3M	1.07%	27
2024 Q2	$58M	Hold	1,268,734	–	–	1.14%	26
2024 Q1	$84M	Hold	1,268,734	–	–	1.54%	22
2023 Q4	$50.4M	Sell	1,268,734 -246,000	-16%	-$7.71M	1.01%	35
2023 Q3	$48.3M	Hold	1,514,734	–	–	1.03%	34
2023 Q2	$60.9M	Sell	1,514,734 -164,683	-10%	-$7.22M	1.1%	35
2023 Q1	$71.7M	Hold	1,679,417	–	–	1.41%	22
2022 Q4	$80.6M	Hold	1,679,417	–	–	1.54%	18
2022 Q3	$63.2M	Hold	1,679,417	–	–	1.17%	29
2022 Q2	$46.4M	Hold	1,679,417	–	–	0.84%	38
2022 Q1	$91.3M	Hold	1,679,417	–	–	1.48%	22
2021 Q4	$98.3M	Hold	1,679,417	–	–	1.26%	30
2021 Q3	$66.4M	Hold	1,679,417	–	–	0.73%	43
2021 Q2	$71.3M	Hold	1,679,417	–	–	0.72%	45
2021 Q1	$103M	Hold	1,679,417	–	–	0.97%	30
2020 Q4	$118M	Hold	1,679,417	–	–	1.04%	26
2020 Q3	$64.8M	Hold	1,679,417	–	–	0.81%	36
2020 Q2	$63M	Buy	+1,679,417	New	+$51.7M	0.89%	34

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

OrbiMed's KROS Position: Q2 2026 in Review

OrbiMed held its Keros Therapeutics (KROS) position steady in Q2 2026 at 759,155 shares worth $8.12M. The position accounts for 0.15% of the portfolio, ranked #88.

OrbiMed first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $118M in Q4 2020. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

OrbiMed held 759,155 shares of Keros Therapeutics worth $8.12M as of Q2 2026.
OrbiMed left its Keros Therapeutics share count unchanged in Q2 2026.
Keros Therapeutics made up 0.15% of OrbiMed's portfolio in Q2 2026, its #88 holding.
OrbiMed first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
OrbiMed's Keros Therapeutics position peaked at $118M in Q4 2020.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.